A recent report published by Precision Business Insights on Female Fertility Drugs Market provides in-depth analysis of segments and sub-segments in the global as well as regional.
According to Precision Business Insights (PBI), the latest report the global female fertility drugs market is expected to be worth USD 3.48 billion in 2021 and projected to grow at 6.3% CAGR from 2022 to 2028.
Female fertility drugs are used in conditions where reproductive system of female is weak or unable to produce offspring due to inability in ovary development. Fertility drugs are extremely effective and first treatment option to overcome infertility. These drugs act by direct stimulation of ovaries or balancing the hormone levels. Factors such as increase in the female population, rise in prevalence of infertility condition due to change in lifestyle, government initiation for the infertility management, and rise in disposable income are anticipated to fuel the women fertility drugs market. Moreover, increase in R&D activities for the development of new drugs, rise in the prevalence of obesity, and increase in the maternal age are expected to boost the market. However, stringent regulatory policies for drug approvals, lack of awareness about women fertility drugs in underdeveloped countries, and alternative infertility treatments such as in vitro fertilization are expected to restrain the market growth.
The global women fertility drugs market is divided into following categories:
North America female fertility drugs market driven by increased cases of female infertility rate due to obesity and lifestyle changes, increase in the R&D activities for the innovation of newer drugs, and rise in awareness about the fertility drugs among the key stakeholders in the region. European market exhibit significant growth rate owing to accessibility of the products, increase in the infertility rate in female due to hormonal imbalance, and lifestyle changes. Moreover, Asia Pacific female fertility drugs market garnered significant share due to rise in female adult population, rise in female genital mutilation, and adoption of newer drugs in the region are the factors expected to upsurge the market share. to name a few. Some of the market developments include Merck KGaA receiving European Commission Grants approval in 2017, for Pergoveris prefilled injection used in the treatment of follicle stimulating hormone (FSH) and Leutinizing hormone (LH) deficiency. According to WHO, approximately 60-80 million couples are suffering from infertility around the world. Moreover, acquisitions & mergers, collaborations, product approvals and product launchings are the strategies followed by the companies for increasing their market revenue share in female fertility drugs market.
Reasons to buy female fertility drugs market Report:
Some of the prominent players in market are Sanofi S.A. (France), Merck KGaA (Germany), Novartis AG (Switzerland), Ferring B.V. (Switzerland),Eli Lilly and Co. (U.S.), Serono, Inc. (U.S.), Novogyne Pharmaceuticals (U.S.), and Pfizer, Inc. (U.S.)
About Precision Business Insights:
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customized market research services based on our client needs.
Precision Business Insights,
Kemp House, 152-160 City Road, London EC1V 2NX
Email: firstname.lastname@example.org Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com